CysLT1 x NKCC2 x Phosphoric diester hydrolases x PDE4 x SLC12A4 x PGI2 receptor x PDE3 x NKCC1 - 药物、适应症、专利

基本信息

关联

1

项与 CysLT1 x NKCC2 x Phosphoric diester hydrolases x PDE4 x SLC12A4 x PGI2 receptor x PDE3 x NKCC1 相关的药物

Ibudilast/Bumetanide

靶点

CysLT1 x NKCC1 x NKCC2 x PDE3 x PDE4 x PGI2 receptor x Phosphoric diester hydrolases x SLC12A4

作用机制

CysLT1拮抗剂 [+7]

在研机构-

原研机构

Stalicla SA初创企业

在研适应症-

非在研适应症

自闭症谱系障碍

最高研发阶段无进展

首次获批国家/地区-

首次获批日期1800-01-20

1

项与 CysLT1 x NKCC2 x Phosphoric diester hydrolases x PDE4 x SLC12A4 x PGI2 receptor x PDE3 x NKCC1 相关的临床试验

NCT04644003 / Completed临床1期

A Phase 1b, Double-Blind, Placebo-Controlled, First-in-Human Study to Evaluate Safety, Tolerability and Pharmacokinetics of a Two-Week Oral Treatment With STP1 in a Subgroup of Patients With Autism Spectrum Disorder

The main purpose of this study is to evaluate safety and tolerability, Pharmacokinetics and Pharmacodynamics, as well as exploratory efficacy of STP1, in a subgroup of patients with Autism Spectrum Disorder (ASD).

开始日期2020-12-07

申办/合作机构

Stalicla SA初创企业

100 项与 CysLT1 x NKCC2 x Phosphoric diester hydrolases x PDE4 x SLC12A4 x PGI2 receptor x PDE3 x NKCC1 相关的临床结果

登录后查看更多信息

100 项与 CysLT1 x NKCC2 x Phosphoric diester hydrolases x PDE4 x SLC12A4 x PGI2 receptor x PDE3 x NKCC1 相关的转化医学

登录后查看更多信息

0 项与 CysLT1 x NKCC2 x Phosphoric diester hydrolases x PDE4 x SLC12A4 x PGI2 receptor x PDE3 x NKCC1 相关的专利（医药）

登录后查看更多信息

分析

对领域进行一次全面的分析。

登录

或

查看完整样例数据